Tags: Chemical Compound, Chemical Substance.

NVP-AUY922 is an experimental drug candidate for the treatment of cancer. It was discovered through a collaboration between The Institute of Cancer Research and the pharmaceutical company Vernalis and licensed to Novartis. It is currently in Phase II clinical trials.NVP-AUY922 is an inhibitor of heat shock protein 90 (Hsp90) which is a chaperone protein that plays a role in the modification of a variety of proteins that have been implicated in oncogenesis.

NVP-AUY_922.svg
IUPAC name
5-(24-Dihydroxy-5-isopropyl-phenyl)-N-ethyl-4-[4-(morpholinomethyl)phenyl]isoxazole-3-carboxamide

Loading...

This page contains content from the copyrighted Wikipedia article "NVP-AUY922"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.